|Description:||1. Ginsenoside has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features. |
2. Ginsenoside F1 significantly reduces ultraviolet-B-induced cell death by maintaining constant levels of Bcl-2 and protects HaCaT cells from apoptosis caused by ultraviolet B irradiation.
3. Ginsenoside F1 has beneficial effects on skin, it reduces α-melanocyte-stimulating hormone-induced melanin secretion in B16F10 cell culture media by 60%, but does not suppress intracellular melanin levels, tyrosinase activity and expression.
4. Ginsenoside F1 has inhibitory effect of elastase and tyrosinase, indicates that ginsenoside F1 have a potential for industrial cosmetic materials.
|Targets:||IL Receptor | Bcl-2/Bax|
|Source:||The roots of Panax ginseng C.A.Mey.|
|Solvent:||DMSO, Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||1.5652 mL||7.8262 mL||15.6524 mL||31.3048 mL||39.131 mL|
|5 mM||0.313 mL||1.5652 mL||3.1305 mL||6.261 mL||7.8262 mL|
|10 mM||0.1565 mL||0.7826 mL||1.5652 mL||3.1305 mL||3.9131 mL|
|50 mM||0.0313 mL||0.1565 mL||0.313 mL||0.6261 mL||0.7826 mL|
|100 mM||0.0157 mL||0.0783 mL||0.1565 mL||0.313 mL||0.3913 mL|
Exp Dermatol. 2015 Feb;24(2):150-2.
|Ginsenoside F1 attenuates hyperpigmentation in B16F10 melanoma cells by inducing dendrite retraction and activating Rho signalling.[Pubmed: 25381719]|
|Ginsenoside F1 (GF1) is a metabolite produced by hydrolysis of the ginsenoside Re and Rg1 in Panax ginseng. According to various studies, high amounts of ginseng components are absorbed in the metabolized form, which are key constituents responsible for the biological effects of P. ginseng. Recently, Ginsenoside F1 was reported to have beneficial effects on skin. However, there has not been a sound understanding of its antimelanogenic effect and underlying molecular mechanisms. In this study, Ginsenoside F1 reduced α-melanocyte-stimulating hormone-induced melanin secretion in B16F10 cell culture media by 60%. However, it did not suppress intracellular melanin levels, tyrosinase activity and expression. Immunofluorescence assay showed that Ginsenoside F1 had no effect on melanosome transport, but significantly induced dendrite retraction. Pull-down assay demonstrated that Ginsenoside F1 primarily modulates the Rho family GTPases resulting in dendrite retraction. Collectively, these data suggest that Ginsenoside F1 could act as a potent skin-whitening agent.|
Exp Dermatol. 2014 Nov;23(11):860-2.
|Role of epidermal γδ T-cell-derived interleukin 13 in the skin-whitening effect of Ginsenoside F1.[Pubmed: 25091975]|
|Ginsenoside F1 (GF1) is a metabolite of ginsenoside Rg1. Although Ginsenoside F1 has several benefits for skin physiology, the effect of Ginsenoside F1 on skin pigmentation has not been reported. We found that a cream containing 0.1% Ginsenoside F1 showed a significant whitening effect on artificially tanned human skin after 8 weeks of application. However, Ginsenoside F1 did not inhibit mRNA expression of tyrosinase or dopachrome tautomerase (DCT) in normal human epidermal melanocytes (NHEMs) or cocultured NHEMs/normal human epidermal keratinocytes. Interestingly, Ginsenoside F1 enhanced production of interleukin 13 (IL-13) from human epidermal γδ T cells. IL-13 significantly reduced the mRNA expression and protein amount of both tyrosinase and DCT and reduced melanin synthesis activities in NHEMs, resulting in visible brightening of NHEM pellet. These results suggest that enhancement of IL-13 production by Ginsenoside F1 from epidermal γδ T cells might play a role in the skin-whitening effect of GF1 via the suppression of tyrosinase and DCT.|
J. Ginseng Res., 2011, 35(1):86-91.
|Ginsenoside F1 Modulates Cellular Responses of Skin Melanoma Cells.[Reference: WebLink]|
|Ginsenoside F1 (G-F1) is an enzymatic metabolite generated from G-Rg1. Although this metabolite has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, the modulatory activity of G-F1 on the functional role of skin-derived cells has not yet been elucidated. In this study, we evaluated the regulatory role of G-F1 on the cellular responses of B16 melanoma cells. G-F1 strongly suppressed the proliferation of B16 cells up to 60% at 200 ug/mL, while only diminishing the viability of HEK293 cells up to 30%. Furthermore, G-F1 remarkably induced morphological change and clustering of B16 melanoma cells. The melanin production of B16 cells was also significantly blocked by G-F1 up to 70%. Interestingly, intracellular signaling events involved in cell proliferation, migration, and morphological change were up-regulated at 1 h incubation but down-regulated at 12 h. Therefore, our results suggest that G-F1 can be applied as a novel anti-skin cancer drug with anti-proliferative and anti-migration features.|
J Invest Dermatol. 2003 Sep;121(3):607-13.
|Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2.[Pubmed: 12925222]|
|Ginsenosides, the major active ingredients of ginseng, show a variety of biomedical efficacies such as antiaging and antioxidation. Here, we investigate the protective activity of the Ginsenoside F1, an enzymatically modified derivative of ginsenoside Rg1, against ultraviolet-B-induced damage in human HaCaT keratinocytes. Ginsenoside F1 significantly reduced ultraviolet-B-induced cell death and protected HaCaT cells from apoptosis caused by ultraviolet B irradiation. Furthermore, Ginsenoside F1 prevented ultraviolet-B-induced cleavage of poly(ADP-ribose) polymerase in HaCaT cells. In search of the molecular mechanism responsible for the antiapoptotic effect of Ginsenoside F1, we find that protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression.|
Korean Journal of Pharmacognosy, 2013, 44(1):10-15.
|Inhibitory effect of elastase and tyrosinase of ginsenoside F1 isolated from Panax ginseng leaves[Reference: WebLink]|
|This study was carried to establish a simple isolation and purification method of Ginsenoside F1 from leaves of Panax ginseng and was to evaluate the inhibitory effect of purified Ginsenoside F1 on the activities of elastase and tyrosinase. The content of Ginsenoside F1 was 90-fold higher in leaves than in root of ginseng. Ginsenoside F1 was isolated from EtOAc fraction between EtOAc and alkalized water of 80% EtOH extract after remove of hydrophobic components. The 50% inhibitory concentration (IC50) of Ginsenoside F1 on elastase activity and tyrosinase activity was 1.07 mM and 1.81 mM, respectively. Especially, inhibitory effect of Ginsenoside F1 on tyrosinase activity was higher than that of arbutin (IC50; 2.20 mM). These results indicate that Ginsenoside F1 have a potential for industrial cosmetic materials.|